5 Einträge gefunden

1. Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.

   1. Schaefer, Martin
   2. Sarkar, Rahul
   3. Knop, Viola
   4. Effenberger, Susanne
   5. Friebe, Astrid
   6. Heinze, Loni
   7. Spengler, Ulrich

   2012 - Forschungsinformationssystem des UKE
2. The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection.

   1. Weich, Viola
   2. Herrmann, Eva
   3. Chung, Tje Lin
   4. Sarrazin, Christoph
   5. Hinrichsen, Holger
   6. Buggisch, Peter
   7. Gerlach, Tilman

   2011 - Forschungsinformationssystem des UKE
3. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients.

   1. Berg, Thomas
   2. Weich, Viola
   3. Teuber, Gerlinde
   4. Klinker, Hartwig
   5. Möller, Bernd
   6. Rasenack, Jens
   7. Hinrichsen, Holger

   2009 - Forschungsinformationssystem des UKE
4. Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection.

   1. von Wagner, Michael
   2. Hofmann, Wolf Peter
   3. Teuber, Gerlinde
   4. Berg, Thomas
   5. Goeser, Tobias
   6. Spengler, Ulrich
   7. Hinrichsen, Holger

   2008 - Forschungsinformationssystem des UKE
5. Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial.

   1. Kronenberger, Bernd
   2. Berg, Thomas
   3. Herrmann, Eva
   4. Hinrichsen, Holger
   5. Gerlach, Tilman
   6. Buggisch, Peter
   7. Spengler, Ulrich

   2007 - Forschungsinformationssystem des UKE